Ribociclib – Medxy AI

Ribociclib Plus Letrozole Shows Potent Activity in Recurrent Low-Grade Serous Ovarian Carcinoma: Results from GOG 3026

By MedXY 01/19/2026

The GOG 3026 phase II trial demonstrates that the combination of ribociclib and letrozole provides significant clinical benefit and durable responses in patients with recurrent low-grade serous carcinoma, representing a major step forward for this chemoresistant malignancy.

news Oncology

Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer

By MedXY 01/13/2026

Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib's therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for personalized adjuvant treatment decisions.

Clinical Updates news Oncology Specialties

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

By MedXY 09/25/2025

Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg as the starting dose with dose reductions for adverse events.